Capital Formation

June 23, 2014

The Jumpstart Our Business Startup (JOBS) Act marks a key departure from the previous one-size...

October 25, 2013

BIO featured Jan Lundberg of Eli Lilly as this year's fireside chat speaker at the BIO...

October 14, 2013

The Jumpstart Our Business Startups (JOBS) Act was signed into law by President Obama on April...

August 14, 2013

Since the 2012 signing of the Jumpstart Our Business Startups Act (JOBS Act), many small...

July 10 2013
A healthy public market is key to the success of the biotech industry, as growing innovators often turn to an IPO to fund late-stage clinical trials.
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.
March 16 2012
On behalf of BIO and its more than 1,100 members, Jim Greenwood submitted a letter to Senate Majority Leader Harry Reid and Minority Leader Mitch McConnell in strong support of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act.
March 6 2012
William D. Waddill, Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals highlights the importance of capital formation to encourage investment in the biotechnology industry and spur job growth across the country.
December 1 2011
On December 1, BIO submitted written testimony to the Senate Committee on Banking, Housing, and Urban Affairs on the importance of implementing policies that will spur job growth through capital formation while protecting investors.  
August 25 2014
Washington, D.C. (August 25, 2014) – The Biotechnology Industry Organization (BIO) today announced the initial list of presenting companies for the 13th Annual BIO Investor Forum. The event is an international investor forum that assembles early and established private companies as well as emerging public biotechs, along with top public and private equity investors, to explore investment trends and opportunities in life sciences. The event will take place October 7-8, 2014 at the Palace Hotel in San Francisco, California. 
July 31 2014
Washington, D.C. (July 31, 2014) – The Biotechnology Industry Organization (BIO) today encourages support for the Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation (COMPETE) Act, introduced today by Senator Tom Carper (D-DE). 
April 7 2014
The EXPIRE Act would extend tax credits that expired at the end of 2013, including several of importance to the biotechnology industry.
September 30 2013
NSF-funded companies focused on drug discovery, diagnostics and other platform technologies.
September 11 2013
Speakers will provide fresh insight, investment opportunities in biotech sector.